|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 463.48 USD | -1.57% |
|
-0.46% | +2.23% |
| 02-10 | Vertex Pharmaceuticals at Turning Point Ahead of Phase 3 Kidney Drug Data, RBC Says | MT |
| 02-09 | Zonebourse Corporate Earnings Calendar: Week of February 9 to 13, 2026 |  |
| Capitalization | 118B 98.81B 90.09B 86.03B 159B 10,650B 166B 1,046B 417B 5,131B 441B 432B 18,134B | P/E ratio 2025 * |
29.9x | P/E ratio 2026 * | 26.2x |
|---|---|---|---|---|---|
| Enterprise value | 108B 90.55B 82.56B 78.83B 146B 9,759B 152B 958B 382B 4,702B 404B 396B 16,617B | EV / Sales 2025 * |
8.99x | EV / Sales 2026 * | 7.93x |
| Free-Float |
99.04% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: Vertex Pharmaceuticals Incorporated
| 1 day | +1.17% | ||
| 1 week | -0.46% | ||
| Current month | -1.37% | ||
| 1 month | -0.08% | ||
| 3 months | +10.04% | ||
| 6 months | +26.45% | ||
| Current year | +2.23% |
| 1 week | 457.74 |  | 478.54 |
| 1 month | 429 | | 485 |
| Current year | 429 | | 487.52 |
| 1 year | 362.5 | | 519.68 |
| 3 years | 283.6 | | 519.88 |
| 5 years | 176.36 | | 519.88 |
| 10 years | 71.46 | | 519.88 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 53 | 2020-03-31 | |
Charles Wagner
DFI | Director of Finance/CFO | 58 | 2019-04-09 |
Agam Upadhyay
CTO | Chief Tech/Sci/R&D Officer | - | 2025-06-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Bruce Sachs
BRD | Director/Board Member | 66 | 1997-12-31 |
Jeffrey Leiden
CHM | Chairman | 70 | 2012-04-30 |
Sangeeta Bhatia
BRD | Director/Board Member | 57 | 2015-06-17 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.57% | -0.46% | -1.38% | +55.84% | 118B | |
| -1.88% | +2.15% | +17.97% | +197.00% | 918B | |
| -0.12% | +2.25% | +54.53% | +46.99% | 574B | |
| -0.37% | -1.43% | +16.86% | +46.29% | 393B | |
| +0.48% | -2.16% | +22.41% | +26.36% | 366B | |
| +1.26% | +3.20% | +24.95% | +52.33% | 301B | |
| +3.11% | +5.39% | +25.08% | +27.29% | 300B | |
| -0.42% | +1.13% | +35.59% | +7.90% | 291B | |
| -3.11% | 0.00% | -49.24% | -38.70% | 223B | |
| -2.97% | +7.70% | +23.70% | +50.37% | 196B | |
| Average | +0.56% | +0.64% | +17.05% | +47.17% | 368.03B | |
| Weighted average by Cap. | +0.66% | +1.20% | +22.16% | +73.29% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 11.98B 10.07B 9.18B 8.77B 16.22B 1,085B 16.95B 107B 42.46B 523B 44.95B 44.02B 1,848B | 13B 10.92B 9.96B 9.51B 17.6B 1,177B 18.39B 116B 46.07B 567B 48.77B 47.76B 2,005B |
| Net income | 3.98B 3.34B 3.05B 2.91B 5.38B 360B 5.62B 35.37B 14.09B 174B 14.92B 14.61B 613B | 4.53B 3.81B 3.47B 3.31B 6.13B 410B 6.41B 40.29B 16.05B 198B 16.99B 16.64B 699B |
| Net Debt | -9.84B -8.27B -7.54B -7.2B -13.32B -891B -13.91B -87.48B -34.85B -429B -36.89B -36.13B -1,517B | -14.5B -12.18B -11.11B -10.6B -19.62B -1,313B -20.5B -129B -51.36B -632B -54.37B -53.25B -2,235B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-02-10 | 463.48 $ | -1.57% | 2,127,907 |
| 26-02-09 | 470.87 $ | -1.48% | 1,794,837 |
| 26-02-06 | 477.92 $ | +4.17% | 1,621,655 |
| 26-02-05 | 458.81 $ | -2.49% | 1,673,029 |
| 26-02-04 | 470.52 $ | +1.05% | 1,362,563 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- VRTX Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition